Why is cardiovascular risk stratification important in hypertensive patients?

References

• Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, . 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–1187.
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Valerio C, Sala C, Esposito A, Masaidi M, Negri F, . Prevalence and correlates of multiple organ damage in a never treated hypertensive population: Role of ambulatory blood pressure. Blood Press Monit. 2008;13:7–13.
   PubMed Web of Science ®Google Scholar
• Magnus P, Beaglehole R. The real contribution of the major risk factors to the coronary epidemics: Time to end the “only-50%”. Arch Intern Med. 2001;161:2657–2660.
   PubMedGoogle Scholar
• Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Smith G, . Heart aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension. A Losartan Intervention for Endpoint-reduction in Hypertension (LIFE) substudy. Am J Hypertens. 2005;18:1430–1436.
   PubMed Web of Science ®Google Scholar
• Levy D, Salomon M, D’Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786–1793.
   PubMed Web of Science ®Google Scholar
• Muiesan ML, Salvetti M, Paini A, Monteduro C, Galbassini G, Bonzi B, . Inappropriate left ventricular mass changes during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension. 2007;49:1077–1083.
   PubMedGoogle Scholar
• Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, . Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45:198–202.
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens. 2008;21:500–508.
   PubMed Web of Science ®Google Scholar
• Leoncini G, Ratto E, Viazzi F, Conti N, Falqui V, Parodi A, . Global risk stratification in primary hypertension: The role of the kidney. J Hypertens. 2008;26:427–432.
   PubMedGoogle Scholar
• Foguet Q, Rodríguez A, Saez M, Ubieto A, Beltrán M, Barceló MA, . Usefulness of optic fundus examination with retinography in initial evaluation of hypertensive patients. Am J Hypertens. 2008;21:400–405.
   PubMedGoogle Scholar
• Coll de Tuero G, Boreu QF, Rodríguez-Poncelas A, Creus R, Sanmartín M, Salleras N, ; VAMPAHICA Study Group. Assessment of self-monitoring of blood pressure in the diagnosis of isolated clinic hypertension. Blood Press. 2006;15:227–236.
   PubMed Web of Science ®Google Scholar
• Dalfó A, Lopez-Contreras J, Gil M. Electrocardiographic diagnosis of left ventricular hypertrophy (LVH). Proposal of modification of Cornell criteria. Am J Hypertens. 1997;10:206A.
   Google Scholar
• Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease study group. Ann Intern Med. 1999;130:461–470.
   PubMed Web of Science ®Google Scholar
• Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Palmer CR, Rosenthal T, . Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension. 2000;35:1038–1042.
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, . Outcomes in hypertensive patients at high cardiovascular risk trated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004;363:2022–2031.
   PubMed Web of Science ®Google Scholar
• Peer N, Steyn K, Dennison CR, Levitt NS, Nyo MT, Nel JH, . Determinants of target organ damage in black hypertensive patients attending primary health care services in Cape Town: The Hi-Hi Study. Am J Hypertens. 2008;21:896–902.
   PubMed Web of Science ®Google Scholar
• Martina B, Nordmann A, Dieterle T, Sigle JP, Bengel G, Kiefer G, . Impact of baseline echocardiography on treatment outcome in primary care patients with newly detected arterial hypertension: A randomized trial. Am J Hypertens. 2006;19:1150–1155.
   PubMedGoogle Scholar
• Schillaci G, Pasqualini L, Vaudo G, Lupattelli G, Pirro M, Gemelli F, . Effect of body weight changes on 24-hour blood pressure and left ventricular mass in hypertension: A 4-year follow-up. Am J Hypertens. 2003;16:634–639.
   PubMedGoogle Scholar
• Vaidya A, Bentley-Lewis R, Jeunemaitre X, Adler GK, Williams JS. Dietary sodium alters the prevalence of electrocardiogram determined left ventricular hypertrophy in hypertension. Am J Hypertens. 2009;22:669–673.
   PubMed Web of Science ®Google Scholar
• Cuspidi C, Parati G. Masked hypertension: An independent predictor of organ damage. J Hypertens. 2007;25:275–279.
   PubMed Web of Science ®Google Scholar
• Van den Born BJ, Hulsman CAA, Hoekstra JBL, Schlingemann RO, Van Montfrans GA. Value of routine funduscopy in patients with hypertension: Systematic review. Br Med J. 2005;331:73–78.
   PubMed Web of Science ®Google Scholar
• Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, . Losartan Intervention for Endpoint reduction in hypertension Study Investigations. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation. 2003;108:684–690.
   PubMed Web of Science ®Google Scholar